RxDoctor Payments DataLook up a doctor →

Heath Gibson, PA

Physician Assistant · Georgetown, KYNPI 1487178299

Payments from drug & device makers

$10,126in general payments, 2019–2025

Across 643 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$740
  • Phathom Pharmaceuticals, Inc.$638
  • Sanofi$509
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$10,01399%
  • Education$1131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,126 in reported general payments places this provider in the 95th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$23,725
Medicare patients
161
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide139$117,254
XifaxanRifaximin29$88,324
CreonLipase/Protease/Amylase19$73,420
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates262$17,614
Dexlansoprazole DrDexlansoprazole39$9,791
Colestipol Hcl54$5,429
Lubiprostone22$2,222
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,094
Pantoprazole Sodium144$1,689
Omeprazole147$1,644
Dicyclomine Hcl56$1,428
Esomeprazole Magnesium59$1,362
Entecavir31$1,045
Ondansetron OdtOndansetron37$968
Lactulose22$820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,888$190,674158 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,234$88,32429 claims
Braintree Laboratories, Inc.Sutab$34$2,09413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Georgetown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →